Reasons for discontinuing the study(full analysis set)
| Reasons for discontinuation | High dose | Low dose | Placebo |
| Subjects | 108 | 55 | 104 |
| Total | 40 (37.0) | 15 (27.3) | 31 (29.8) |
| Progression of disease | 8 (7.4) | 0 (0.0) | 15 (14.4) |
| Death | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 10% decline in VC | 5 (4.6) | 0 (0.0) | 11 (10.6) |
| Worsening of respiratory symptoms | 3 (2.8) | 0 (0.0) | 4 (3.7) |
| Acute exacerbation | 4 (3.7) | 2 (3.6) | 4 (3.8) |
| Adverse events# | 15 (13.9) | 9 (16.4) | 7 (6.7) |
| Photosensitivity | 3 (2.8) | 2 (3.6) | 0 (0.0) |
| Lung carcinoma | 2 (1.8) | 1 (1.8) | 1 (0.9) |
| Fever | 2 (1.8) | 0 (0.0) | 0 (0.0) |
| Respiratory failure¶ | 2 (1.8) | 0 (0.0) | 0 (0.0) |
| Rash | 1 (0.9) | 1 (1.8) | 0 (0.0) |
| AST and/or ALT increase | 1 (0.9) | 1 (1.8) | 0 (0.0) |
| Gastric ulcer | 1 (0.9) | 0 (0.0) | 0 (0.0) |
| Anorexia | 1 (0.9) | 0 (0.0) | 0 (0.0) |
| Muscle pain | 1 (0.9) | 0 (0.0) | 0 (0.0) |
| Dysgeusia | 1 (0.9) | 0 (0.0) | 0 (0.0) |
| Loss of consciousness | 1 (0.9) | 0 (0.0) | 0 (0.0) |
| Respiratory tract infection | 0 (0.0) | 2 (3.6) | 0 (0.0) |
| Fatigue, drowsiness | 0 (0.0) | 1 (1.8) | 0 (0.0) |
| Rheumatoid arthritis | 0 (0.0) | 1 (1.8) | 0 (0.0) |
| Electrocardiogram abnormal | 0 (0.0) | 0 (0.0) | 2 (1.9) |
| Nausea | 0 (0.0) | 0 (0.0) | 1 (0.9) |
| Lung neoplasm | 0 (0.0) | 0 (0.0) | 1 (0.9) |
| MPO–ANCA increase | 0 (0.0) | 0 (0.0) | 1 (0.9) |
| Cerebral thrombosis | 0 (0.0) | 0 (0.0) | 1 (0.9) |
| Suicide | 0 (0.0) | 0 (0.0) | 1 (0.9) |
| Upper respiratory tract infection | 0 (0.0) | 0 (0.0) | 1 (0.9) |
| Pneumothorax | 0 (0.0) | 0 (0.0) | 1 (0.9) |
| Consent withdrawn | 12 (11.1) | 2 (3.6) | 4 (3.8) |
| Other | 1 (0.9) | 2 (3.6) | 1 (1.0) |
Data are presented as n or n (%). VC: vital capacity; AST: aspartate aminotransferase; ALT: alanine aminotransferase: MPO–ANCA: myeloperoxidase-anti-neutrophil cytoplasmic antibody. #: other than acute exacerbation; ¶: one case was respiratory failure due to traumatic shock caused by a traffic accident.